Multicenter International Study of the Consensus Immunoscore for the Prediction of Relapse and Survival in Early-Stage Colon Cancer.

Authors

Bernhard Mlecnik
Alessandro Lugli
Gabriela Bindea
Florence Marliot
Carlo Bifulco, Earle A. Chiles Research Institute, Robert W. Franz Cancer Research Center, Providence Portland Medical Center, Portland, ORFollow
Jiun-Kae Jack Lee
Inti Zlobec
Tilman T Rau
Martin D Berger
Iris D Nagtegaal
Elisa Vink-Börger
Arndt Hartmann
Carol I Geppert
Julie Kolwelter
Susanne Merkel
Robert Grützmann
Marc Van den Eynde
Anne Jouret-Mourin
Alex Kartheuser
Daniel Léonard
Christophe Remue
Julia Wang
Prashant Bavi
Michael H A Roehrl
Pamela S Ohashi
Linh T Nguyen
SeongJun Han
Heather L MacGregor
Sara Hafezi-Bakhtiari
Bradly G Wouters
Giuseppe V Masucci
Emilia K Andersson
Eva Zavadova
Michal Vocka
Jan Spacek
Lubos Petruzelka
Bohuslav Konopasek
Pavel Dundr
Helena Skalova
Kristyna Nemejcova
Gerardo Botti
Fabiana Tatangelo
Paolo Delrio
Gennaro Ciliberto
Michele Maio
Luigi Laghi
Fabio Grizzi
Tessa Fredriksen
Bénédicte Buttard
Lucie Lafontaine
Pauline Maby
Amine Majdi
Assia Hijazi
Carine El Sissy
Amos Kirilovsky
Anne Berger
Christine Lagorce
Christopher Paustian
Carmen Ballesteros-Merino
Jeroen Dijkstra
Carlijn van de Water
Shannon van Lent-van Vliet
Nikki Knijn
Ana-Maria Mușină
Dragos-Viorel Scripcariu
Boryana Popivanova
Mingli Xu
Tomonobu Fujita
Shoichi Hazama
Nobuaki Suzuki
Hiroaki Nagano
Kiyotaka Okuno
Toshihiko Torigoe
Noriyuki Sato
Tomohisa Furuhata
Ichiro Takemasa
Prabhu Patel
Hemangini H Vora
Birva Shah
Jayendrakumar B Patel
Kruti N Rajvik
Shashank J Pandya
Shilin N Shukla
Yili Wang
Guanjun Zhang
Yutaka Kawakami
Francesco M Marincola
Paolo A Ascierto
Bernard A Fox, Chiles Research Institute Providence Portland Medical CenterFollow
Franck Pagès
Jérôme Galon

Document Type

Article

Publication Date

1-8-2023

Publication Title

Cancers (Basel)

Keywords

oregon; portland; ppmc; chiles

Abstract

BACKGROUND: The prognostic value of Immunoscore was evaluated in Stage II/III colon cancer (CC) patients, but it remains unclear in Stage I/II, and in early-stage subgroups at risk. An international Society for Immunotherapy of Cancer (SITC) study evaluated the pre-defined consensus Immunoscore in tumors from 1885 AJCC/UICC-TNM Stage I/II CC patients from Canada/USA (Cohort 1) and Europe/Asia (Cohort 2).

METHODS: Digital-pathology is used to quantify the densities of CD3+ and CD8+ T-lymphocyte in the center of tumor (CT) and the invasive margin (IM). The time to recurrence (TTR) was the primary endpoint. Secondary endpoints were disease-free survival (DFS), overall survival (OS), prognosis in Stage I, Stage II, Stage II-high-risk, and microsatellite-stable (MSS) patients.

RESULTS: High-Immunoscore presented with the lowest risk of recurrence in both cohorts. In Stage I/II, recurrence-free rates at 5 years were 78.4% (95%-CI, 74.4-82.6), 88.1% (95%-CI, 85.7-90.4), 93.4% (95%-CI, 91.1-95.8) in low, intermediate and high Immunoscore, respectively (HR (Hi vs. Lo) = 0.27 (95%-CI, 0.18-0.41);

CONCLUSION: In early CC, low Immunoscore reliably identifies patients at risk of relapse for whom a more intensive surveillance program or adjuvant treatment should be considered.

Clinical Institute

Digestive Health

Clinical Institute

Cancer

Department

Gastroenterology

Department

Oncology

Department

Earle A. Chiles Research Institute

Share

COinS